BlackRock Institutional Trust’s Teva Pharmaceuticals TEVA Stock Holding History

BlackRock Institutional Trust’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$461M	Buy	12,724,714 +12,577,643	+8,552%	+$502M	0.07%	287
2016 Q3	$6.77M	Sell	147,071 -38,450	-21%	-$2.01M	﹤0.01%	2567
2016 Q2	$9.32M	Buy	185,521 +9,000	+5%	+$479K	﹤0.01%	2329
2016 Q1	$9.45M	Buy	176,521 +3,190	+2%	+$187K	﹤0.01%	2292
2015 Q4	$11.4M	Buy	173,331 +31,494	+22%	+$1.95M	﹤0.01%	2240
2015 Q3	$8.01M	Sell	141,837 -90,148	-39%	-$5.85M	﹤0.01%	2436
2015 Q2	$13.7M	Sell	231,985 -238,721	-51%	-$14.7M	﹤0.01%	2182
2015 Q1	$29.3M	Buy	470,706 +267,610	+132%	+$15.6M	﹤0.01%	1686
2014 Q4	$11.7M	Buy	203,096 +64,987	+47%	+$3.62M	﹤0.01%	2275
2014 Q3	$7.42M	Buy	138,109 +31,596	+30%	+$1.67M	﹤0.01%	2490
2014 Q2	$5.58M	Buy	106,513 +6,701	+7%	+$343K	﹤0.01%	2736
2014 Q1	$5.27M	Buy	99,812 +38,512	+63%	+$1.78M	﹤0.01%	2760
2013 Q4	$2.46M	Sell	61,300 -33,941	-36%	-$1.34M	﹤0.01%	3075
2013 Q3	$3.6M	Sell	95,241 -211,882	-69%	-$8.27M	﹤0.01%	2874
2013 Q2	$12M	Buy	+307,123	New	+$12M	﹤0.01%	2190

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

BlackRock Institutional Trust's TEVA Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Teva Pharmaceuticals (TEVA) stake by 8,552% in Q4 2016, buying an estimated $502M and bringing the position to 12,724,714 shares worth $461M. The position accounts for 0.07% of the portfolio, ranked #287.

BlackRock Institutional Trust first reported a position in TEVA in Q2 2013 and has held it in 15 quarters since. 739 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

BlackRock Institutional Trust held 12,724,714 shares of Teva Pharmaceuticals worth $461M as of Q4 2016.
BlackRock Institutional Trust bought 12,577,643 Teva Pharmaceuticals shares in Q4 2016, an estimated $502M.
Teva Pharmaceuticals made up 0.07% of BlackRock Institutional Trust's portfolio in Q4 2016, its #287 holding.
BlackRock Institutional Trust first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
739 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.